Watson Pharmaceuticals is to acquire Arrow Group for $1.75bn (€1.26bn), adding to the company’s manufacturing network and providing it with the expertise needed to enter the biogenerics market.
The US Food and Drug Administration (FDA) has withdrawn its
long-standing block on the manufacture of new products at Watson
Pharmaceuticals' facility in Davie, Florida.
An end may be in sight to the long-running problems with the
Florida manufacturing facility acquired by US brand and generic
company Watson Pharmaceuticals with Andrx Corporation in November
2006.
As it consolidates its manufacturing operations in the US, Watson
Pharmaceuticals has received a warning letter from the US Food and
Drug Administration (FDA) accusing it of using the wrong
ingredients in the production of capsules,...